Literature DB >> 20128675

Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients.

Sema Içöz1, Erdem Tüzün, Murat Kürtüncü, Hacer Durmuş, Melike Mutlu, Mefkure Eraksoy, Gülşen Akman-Demir.   

Abstract

Anti-aquaporin-4 (Aqp-4) antibody and complement system have emerged as major pathogenic factors in neuromyelitis optica (NMO). To test the significance of interleukin-6 (IL-6), another important humoral immunity factor, in NMO pathogenesis, we measured serum and cerebrospinal fluid (CSF) IL-6 levels of 23 NMO, 11 transverse myelitis, 16 optic neuritis, 27 relapsing remitting multiple sclerosis patients, and 20 neurologically normal controls. NMO and transverse myelitis patients had higher serum and CSF IL-6 levels than other groups. Particularly, anti-Aqp-4 positive NMO patients (n = 12) had higher serum/CSF IL-6 levels than anti-Aqp-4 negative patients (n = 11) and CSF IL-6 levels correlated with anti-Aqp-4 levels and disease severity of the NMO patients. Our results suggest that IL-6 is involved in NMO pathogenesis presumably via anti-Aqp-4 associated mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128675     DOI: 10.3109/00207450903428970

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  35 in total

Review 1.  Janus-like effects of type I interferon in autoimmune diseases.

Authors:  Robert C Axtell; Chander Raman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

3.  Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor.

Authors:  Shannon R Hinson; Ian C Clift; Ningling Luo; Thomas J Kryzer; Vanda A Lennon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 4.  Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.

Authors:  Sean J Pittock; Claudia F Lucchinetti
Journal:  Ann N Y Acad Sci       Date:  2015-06-10       Impact factor: 5.691

5.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Authors:  Norio Chihara; Toshimasa Aranami; Wakiro Sato; Yusei Miyazaki; Sachiko Miyake; Tomoko Okamoto; Masafumi Ogawa; Tatsushi Toda; Takashi Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

6.  Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.

Authors:  Takashi Kageyama; Mika Komori; Katsuichi Miyamoto; Akihiko Ozaki; Toshihiko Suenaga; Ryosuke Takahashi; Susumu Kusunoki; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2012-10-18       Impact factor: 4.849

Review 7.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 8.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

Review 9.  Pain in neuromyelitis optica--prevalence, pathogenesis and therapy.

Authors:  Monika Bradl; Yoko Kanamori; Ichiro Nakashima; Tatsuro Misu; Kazuo Fujihara; Hans Lassmann; Jürgen Sandkühler
Journal:  Nat Rev Neurol       Date:  2014-07-29       Impact factor: 42.937

Review 10.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.